Online Inquiry
Recombinant Human Fibroblast growth factor receptor 3 (FGFR3), partial (Active)
SPP-01884
| Size | Price |
| 1 mg | Online Inquiry |
| 500 μg | Online Inquiry |
| 50 μg | Online Inquiry |
| 10 μg | Online Inquiry |
| Target Information | |
|---|---|
| Species | Homo sapiens |
| Target Name | FGF Receptor |
| UniProt No. | P22607 |
| Subcellular Location | Isoform 1: Cell membrane, Single-pass type I membrane protein, Cytoplasmic vesicle, Endoplasmic reticulum |
| Tissue Specificity | Expressed in brain, kidney and testis. Very low or no expression in spleen, heart, and muscle. In 20- to 22-week old fetuses it is expressed at high level in kidney, lung, small intestine and brain, and to a lower degree in spleen, liver, and muscle. |
| Gene Abbr. | FGFR3 |
| Full Name | fibroblast growth factor receptor 3 |
| Alias | ACH, CD333, CEK2, HSFGFR3EX, JTK4 |
| Introduction | Fibroblast growth factors (FGFs) produce mitogenic and angiogenic effects in target cells by signaling through cell surface receptor tyrosine kinases. There are four members of the FGF receptor family: FGFR1 (flg), FGFR2 (bek, KGFR), FGFR3, and FGFR4. Each receptor contains an extracellular ligand binding domain, a transmembrane domain, and a cytoplasmic kinase domain. Following ligand binding and dimerization, the receptors are phosphorylated at specific tyrosine residues. Seven tyrosine residues in the cytoplasmic tail of FGFR1 can be phosphorylated: Tyr463, 583, 585, 653, 654, 730, and 766. Tyr653 and Tyr654 are important for catalytic activity of activated FGFR and are essential for signaling. The other phosphorylated tyrosine residues may provide docking sites for downstream signaling components such as Crk and PLCγ.Activating mutations within fibroblast growth factor receptor 3 (FGFR-3) are responsible for human skeletal dysplasias including achondroplasia and the neonatal lethal syndromes thanatophoric dysplasia types I and II. Several of these same FGFR-3 mutations as well as overexpression of FGFR-3 proteins have also been identified somatically in human cancers, including multiple myeloma, bladder carcinoma and cervical cancer. Thus, FGFR-3 may represent a potential target for therapy. |
| Product Details | |
|---|---|
| Product Type | Recombinant Protein |
| Product Form | Lyophilized powder |
| Buffer before Lyophilization | Lyophilized from a 0.2 μm filtered 1xPBS, pH 7.4. |
| Storage & Handling | |
|---|---|
| Storage Temp. | Store at -20 °C upon receipt unless otherwise instructed. |
| Handling | Aliquoting is necessary for mutiple use. Avoid repeated freeze-thaw cycles. |
For research use only. Not intended for any clinical use. No products from CD BioSciences may be resold, modified for resale or used to manufacture commercial products without prior written approval from CD BioSciences.